Upsher-Smith

Executive Summary

Upsher-Smith Laboratories, LLC, a privately-held U.S. pharmaceutical company founded in 1919 and headquartered in Maple Grove, Minnesota, manufactures and markets a broad portfolio of brand and generic drugs. The company emphasizes high-quality manufacturing and reliable supply, serving therapeutic areas such as neurology, cardiology, and pain management. As a generics-focused firm with a century-long history, Upsher-Smith competes in a fragmented market where consistent production and regulatory compliance are critical. The company's private status limits public disclosure of financials and pipeline details; however, its longevity suggests a stable position in the generic drug sector. Recent trends in generic drug pricing and consolidation may impact Upsher-Smith's margins, but its reputation for quality and supply chain reliability could support steady demand from healthcare providers. The company's lack of public equity means that investment opportunities are limited to private transactions or strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of a generic drug application60% success
• TBDExpansion of manufacturing capacity or facility upgrade50% success
• Q2 2027Launch of a new authorized generic or first-to-file product40% success